Cotinga Pharmaceuticals Inc. (COTQF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 83.84 Thousand | 170.67 Thousand | 182.43 Thousand | 172.63 Thousand | 1.01 Million | 835.54 Thousand |
| Gross Profit | -83.84 Thousand | -170.67 Thousand | -182.43 Thousand | -172.63 Thousand | -1.01 Million | -835.54 Thousand |
| Operating Expenses | 1.92 Million | 4.75 Million | 4.99 Million | 3.04 Million | 2.09 Million | 1.88 Million |
| Selling, General and Administrative Expenses | 1.41 Million | 2.6 Million | 3 Million | 1.84 Million | 2.17 Million | 1.88 Million |
| Research and Development Expenses | 502.51 Thousand | 2.15 Million | 1.99 Million | 1.2 Million | 1.11 Million | 971.83 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 2 Million | 4.93 Million | 5.18 Million | 3.22 Million | 3.1 Million | 2.71 Million |
| Operating Income | -2 Million | -4.93 Million | -5.18 Million | -3.22 Million | -3.18 Million | -2.71 Million |
| Interest Expense | - | 1438.00 | 2356.00 | 1004.00 | 64.22 Thousand | 20.15 Thousand |
| Income Tax Expense | 38.85 Thousand | -34.23 Thousand | -105.48 Thousand | -90.52 Thousand | -0.38 | 0.29 |
| Earnings before Tax | -1.96 Million | -3.84 Million | -4.64 Million | -4.02 Million | -3.14 Million | -2.73 Million |
| Net Income | -2 Million | -3.8 Million | -4.54 Million | -3.93 Million | -3.14 Million | -2.73 Million |
| Earnings Per Share Basic | -0.09 | -0.24 | -0.31 | -0.31 | -0.29 | -0.31 |
| Earnings Per Share Diluted | -0.09 | -0.24 | -0.31 | -0.31 | -0.29 | -0.31 |
| Weighted Average Shares Outstanding | 21.95 Million | 15.96 Million | 14.84 Million | 12.71 Million | 10.86 Million | 8.91 Million |
| Weighted Average Shares Outstanding (Diluted) | 21.95 Million | 15.96 Million | 14.84 Million | 12.71 Million | 10.86 Million | 8.91 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1.92 Million | -6.05 Million | -5.95 Million | -3.84 Million | -3.15 Million | -2.44 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 FY | 2018 Q4 | 2018 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 108.95 | 120.35 | 126.54 | 83.84 Thousand | 103.92 | 53.70 |
| Gross Profit | -108.95 | -120.35 | -126.54 | -83.84 Thousand | -103.92 | -53.70 |
| Operating Expenses | 261.17 | 254.06 | 249.54 | 1.92 Million | 597.94 | 158.95 |
| Selling, General and Administrative Expenses | 246.84 | 252.19 | 258.15 | - | 441.88 | 217.04 |
| Research and Development Expenses | 108.95 | 120.35 | 126.54 | - | 93.91 | 103.68 |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 370.12 | 374.41 | 376.08 | 2 Million | 701.86 | 212.64 |
| Operating Income | -355.79 | -372.54 | -384.69 | -2 Million | -545.80 | -270.74 |
| Interest Expense | - | - | - | 3479.78 | - | - |
| Income Tax Expense | - | - | - | 38.85 Thousand | - | - |
| Earnings before Tax | -403.21 | -407.46 | -399.13 | -1.96 Million | -702.58 | -212.97 |
| Net Income | -403.21 | -407.46 | -399.13 | -2 Million | -702.58 | -212.97 |
| Earnings Per Share Basic | -0.02 | -0.02 | -0.02 | - | -0.03 | -0.01 |
| Earnings Per Share Diluted | -0.02 | -0.02 | -0.02 | - | -0.03 | -0.01 |
| Weighted Average Shares Outstanding | 21.98 Thousand | 21.98 Thousand | 21.98 Thousand | 21.95 Million | 22.21 Thousand | 21.98 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 21.98 Thousand | 21.98 Thousand | 21.98 Thousand | 21.95 Million | 22.21 Thousand | 21.98 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -343.36 | -360.00 | -371.90 | - | -529.11 | -249.95 |
| Earnings Before Tax Margin | - | - | - | - | - | - |
RNC
600691
CNTB
AZM
GLENMARK
BPCR